

| | | |
|--|---------------------|--------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b)) | Attorney Docket No. | 50164/026005 |
| | Serial No. | 10/777,517 |
| | Applicant | Jost-Price et al. |
| | Filing Date | February 12, 2004 |
| | Group | 1612 |
| | IDS Filed | September 22, 2008 |

| U.S. PATENT DOCUMENTS | | | |
|-----------------------|-----------------|------------------|-----------------------|
| Examiner's Initials | Document Number | Publication Date | Patentee or Applicant |
| | | | |

| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | |
|--|-----------------|------------------|--------------------------|----------------------|
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Translation (Yes/No) |
| | | | | |

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | |
|---|--|
| /B.P./ | Ahmed et al., "Treatment of Refractory Temporal Arteritis with Adalimumab," <i>Clin. Rheumatol.</i> 26:1353-1355, 2007. |
| /B.P./ | Ardizzone et al., "Inflammatory Bowel Disease: New Insights Into Pathogenesis and Treatment," <i>J. Intern. Med.</i> 252:475-496, 2002. |
| /B.P./ | Badger et al., "Disease-Modifying Activity of SB 242235, A Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, in Rat Adjuvant-Induced Arthritis," <i>Arth. Rheum.</i> 43:175-183, 2000. |
| /B.P./ | Beck et al., "Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?" <i>Acta. Neurol. Scand.</i> 78:318-323, 1998. |
| /B.P./ | Braun et al., "Anti-Tumour Necrosis Factor α Therapy for Ankylosing Spondylitis: International Experience," <i>Ann. Rheum. Dis.</i> 61:iii51-iii60, 2002. |
| /B.P./ | Braun et al., "Therapy of Ankylosing Spondylitis and Other Spondyloarthritides: Established Medical Treatment, Anti-TNF- α Therapy and Other Novel Approaches," <i>Arth. Res.</i> 4:307-321, 2002. |
| /B.P./ | Cantini et al., "Treatment of Longstanding Active Giant Cell Arteritis with Infliximab: Report of Four Cases," <i>Arth. Rheum.</i> 44:2933-2935, 2001. |
| /B.P./ | Crew et al., "Transgenic Mice Expressing a Truncated <i>Peromyscus leucopus</i> TNF- α Gene Manifest an Arthritis Resembling Ankylosing Spondylitis," <i>J. Interferon Cytokine Res.</i> 18:219-225, 1998. |
| /B.P./ | Durie et al., "Collagen-Induced Arthritis as a Model of Rheumatoid Arthritis," <i>Clin. Immunol. Immunopathol.</i> 73:11-18, 1994. |
| EXAMINER | /Benjamin Packard/ |
| DATE CONSIDERED | 12/31/2008 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

| | |
|--|---|
| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b)) | Attorney Docket No. 50164/026005 Serial No. 10/777,517 Applicant Jost-Price et al. Filing Date February 12, 2004 Group 1612 IDS Filed September 22, 2008 |
|--|---|

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | |
|---|--|
| /B.P./ | Edwards, "PEGylated Recombinant Human Soluble Tumour Necrosis Factor Receptor Type 1 (r-Hu-sTNF-RI): Novel High Affinity TNF Receptor Designed for Chronic Inflammatory Diseases," <i>Ann. Rheum. Dis.</i> 58:173-181, 1999. |
| /B.P./ | Elenkov et al., "Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity," <i>Ann. N.Y. Acad. Sci.</i> 966:290-303, 2002. |
| /B.P./ | Ettehad et al., "Elevated Tumour Necrosis Factor-Alpha (TNF- α) Biological Activity in Psoriatic Skin Lesions," <i>Clin. Exp. Immunol.</i> 96:146-151, 1994. |
| /B.P./ | Feldmann et al., "Anti-TNF α Therapy of Rheumatoid Arthritis: What Have We Learned?" <i>Annu. Rev. Immunol.</i> 19:163-196, 2001. |
| /B.P./ | Field et al., "Immuno-Localisation of Tumour Necrosis Factor and Its Receptors in Temporal Arteritis," <i>Rheumatol. Int.</i> 17:113-118, 1997. |
| /B.P./ | Ganesan et al., "Therapeutic Inhibitors of Tumor Necrosis Factor in Crohn's Disease," <i>Curr. Opin. Invest. Drugs</i> 3:1301-1306, 2002. |
| /B.P./ | Gorman et al., "Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α ," <i>N. Eng. J. Med.</i> 346:1349-1356, 2002. |
| /B.P./ | Khoury et al., "Changes in Serum Levels of ICAM and TNF-R Correlate with Disease Activity in Multiple Sclerosis," <i>Neurology</i> 53:758, 1999. |
| /B.P./ | Krueger et al., "Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis," <i>Arch. Dermatol.</i> 140:218-225, 2004. |
| /B.P./ | Lichtenstein, "Is Infliximab Effective for Induction of Remission in Patients with Ulcerative Colitis?" <i>Inflammatory Bowel Diseases</i> 7:89-93, 2001. |
| /B.P./ | Mashkovsky, "Interactions Between Medicaments," <i>Novaya Volna</i> 1:11, 2001. |
| /B.P./ | Mashkovsky, "Interactions Between Medicaments," <i>Novaya Volna</i> 1:11, 2001. (English translation) |
| /B.P./ | Mashkovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001. |
| /B.P./ | Mashkovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001. (English translation) |
| /B.P./ | Martínez-Taboada et al., "A Double-Blind Placebo Controlled Trial of Etanercept in Patients with Giant Cell Arteritis and Corticosteroid Side Effects," <i>Ann. Rheum. Dis.</i> 67:625-630, 2008. |
| /B.P./ | Mattey et al., "Association of Giant Cell Arteritis and Polymyalgia Rheumatica with Different Tumor Necrosis Factor Microsatellite Polymorphisms," <i>Arth. Rheum.</i> 43:1749-1755, 2000. |

| | |
|---|----------------------------|
| EXAMINER * /Benjamin Packard/ | DATE CONSIDERED 12/31/2008 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

| | |
|--|---|
| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b)) | Attorney Docket No. 50164/026005 Serial No. 10/777,517 Applicant Jost-Price et al. Filing Date February 12, 2004 Group 1612 IDS Filed September 22, 2008 |
|--|---|

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | |
|---|--|
| /B.P./ | Migliore et al., "TNF-alpha Blockade Induce Clinical Remission in Patients Affected by Polymyalgia Rheumatica Associated to Diabetes Mellitus and/or Osteoporosis: a Seven Cases Report," <i>Eur. Rev. Med. Pharmacol. Sci.</i> 9:373-378, 2005. |
| /B.P./ | Moreland et al., "Etanercept Therapy in Rheumatoid Arthritis," <i>Ann. Intern. Med.</i> 130:478-486, 1999. |
| /B.P./ | Mpofu et al., "Anti-TNF- α Therapies: They Are All the Same (Aren't They?)," <i>Rheumatology</i> 44:271-272, 2005. |
| /B.P./ | Murch et al., "Location of Tumour Necrosis Factor α by Immunohistochemistry in Chronic Inflammatory Bowel Disease," <i>Gut</i> 34:1705-1709, 1993. |
| /B.P./ | Nanda et al., "Etanercept: a Clinical Review of Current and Emerging Indications," <i>Expert. Opin. Pharmacother.</i> 5:1175-1186, 2004. |
| /B.P./ | Nikolaus et al., "Mechanisms in Failure of Infliximab for Crohn's Disease," <i>Lancet</i> 356:1475-1479, 2000. |
| /B.P./ | Raza, "Anti-TNF Therapies in Rheumatoid Arthritis, Crohn's Disease, Sepsis, and Myelodysplastic Syndromes," <i>Microsc. Res. Tech.</i> 50:229-235, 2000. |
| /B.P./ | Sandborn et al., "Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial," <i>Gastroenterology</i> 121:1088-1094, 2001. |
| /B.P./ | Sands, "Biological Therapies for Ulcerative Colitis," <i>Acta Gastro-Enterologica Belgica</i> 64:205-209, 2001. |
| /B.P./ | Schreiber et al., "Tumour Necrosis Factor α and Interleukin 1β in Relapse of Crohn's Disease," <i>Lancet</i> 353:459-461, 1999. |
| /B.P./ | Selmaj et al., "Identification of Lymphotoxin and Tumor Necrosis Factor in Multiple Sclerosis Lesions," <i>J. Clin. Invest.</i> 87:949-954, 1991. |
| /B.P./ | Sharief et al., "Association Between Tumor Necrosis Factor- α and Disease Progression in Patients with Multiple Sclerosis," <i>N. Eng. J. Med.</i> 325:467-472, 1991. |
| /B.P./ | Shen et al., "Current Therapeutic Recommendations, <i>Infliximab for Ulcerative Colitis</i> ," <i>J. Clin. Gastroenterol.</i> 38:741-745, 2004. |
| /B.P./ | Shou et al., "Identification of Blood Biomarkers of Rheumatoid Arthritis by Transcript Profiling of Peripheral Blood Mononuclear Cells From the Rat Collagen-Induced Arthritis Model," <i>Arthritis Res. Ther.</i> 8:R28, 2006. |
| /B.P./ | Sieper et al., "New Treatment Options in Ankylosing Spondylitis: a Role for Anti-TNF α Therapy," <i>Ann. Rheum. Dis.</i> 60:iii58-iii61, 2001. |
| /B.P./ | Song et al., "Serotonin Reuptake Inhibitors Reverse the Impairments in Behavior, Neurotransmitter and Immune Functions in the Olfactory Bulbectomized Rat," <i>Human Psychopharmacol.</i> 9:135-146, 1994. |

| | |
|---|----------------------------|
| EXAMINER /Benjamin Packard/ | DATE CONSIDERED 12/31/2008 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

| | | | |
|--|--|---------------------|--------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50164/026005 |
| <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> | | Serial No. | 10/777,517 |
| | | Applicant | Jost-Price et al. |
| | | Filing Date | February 12, 2004 |
| | | Group | 1612 |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | September 22, 2008 |

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | |
|---|---|
| /B.P./ | Vladic et al., "Cerebrospinal Fluid and Serum Protein Levels of Tumour Necrosis Factor-Alpha (TNF- α), Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R gp80) in Multiple Sclerosis Patients," <i>Cytokine</i> 20:86-89, 2002. |

| | |
|---|----------------------------|
| EXAMINER /Benjamin Packard/ | DATE CONSIDERED 12/31/2008 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |